Material and methods enzyme reaction rate analyser with the reaction course displayed on a chart recorder, and consequently no repetitive sampling or multiple assaying is required. Our method gives quantitative results for bone and liver isoenzymes together with a composite value for placental + intestinal AP and is sufficiently sensitive for normal serum isoenzyme activities.
Electrophoretic methods for alkaline phosphatase (AP) isoenzymes can play an important role in the recognition of rare variant isoenzyrnes-2 and the 'origin' liver band of cholestasis" but give difficulties with resolution, quantitation, and sensitivity and are not well suited for use in the routine clinical laboratory. Available methods more applicable to routine work involve selective degradation by heat and by urea for bone and liver isoenzyrnes! or use selective inhibitors such as phenylalanine and levamisole for placental and intestinal isoenzymes." 6 As these reagents are only partially selective, the procedures have the disadvantages that (a) several separate analyses have to be made on each specimen with complex calculation to elicit individual isoenzyme activities, and (b) results are necessarily based on the small levels of activity remaining after the degradation/inhibition procedure. This latter disadvantage has been overcome more recently by methods that monitor the whole course of the heat degradation of serum AP isoenzymes.? 8 This necessitates a series of separate analyses on each specimen, and, to cope with this, one recent publication describes the use of an Auto-Analyser arranged to sample serum repetitively during the course of the heat treatment,"
We describe here a degradative procedure which also follows the complete course of AP inhibition but which uses urea for the enzyme inhibition. The entire reaction is carried out in one cuvette of an shown in Fig. 1 as curve H. The individual exponential component terms of equation 2 are shown as curves H] and H 2 • Calculation of the curves HI and H 2 (and hence values of C I and C ) is straightforward. Figure 2 shows curve H plotted on semilogarithmic graph paper. Initially, the log plot is not straight, but at the point where the less stable isoenzyme has entirely decayed the curve becomes linear. For relatively Ions t then we have:
Extrapolation of this linear portion gives the log plot of curve H 2 • The slope has the value of -k 2 and the intercept the value C 2 . By subtraction of H 2 from H the curve HI is obtained, and on a log plot it is also a straight line with slope of -kj and intercept Cj • The change in total AP activity with time in the presence of urea can be displayed with a reaction rate analyser connected to a chart recorder showing optical density due to accumulated product. Curves A' and H' (Fig. 3 ) are typical traces. The residual enzyme activity at any instant is given by the slope at that point. Activities at points along the curve might therefore be found by graphical estimation of slopes, but as this is subject to considerable inaccuracies the following alternative approach is necessary. The height of curve A' at any instant represents the total accumulated product of the enzymatic reaction. The instantaneous activity is given by equation (1), and so the total accumulated product P is given by the integral of (1) with respect to time:
This is the equation of the line shown in Fig. 3 as curve A' . The latter part of curve A' is linear (from term Cjt), and the value of Cjt can be calculated from the slope. Subtraction of this term from equation (3) gives: (6) (7) and following substraction:
product yet to be formed before inhibition is complete. Curve D is also comprised of a sum of exponentials (see equation 5) and can be analysed into its constitutent components in a manner similar to that shown in Fig. 2 (for curve B) to yield slope and intercept for the longer half life component in the first instance and, following subtraction, values for the shorter half-life component:
METHOD FOR CALCULATION OF RESULTS
A graphical method will be described to illustrate the principles. In the authors' laboratory, however, a chart reader is used to digitise the graph which, in the form of punched paper tape, is processed on a minicomputer using a FORTRAN program. This program calculates and displays the logarithmic plots, finds slopes and intercepts for the exponential components by a least squares regression line, and outputs the calculated isoenzyme activities. Results are calculated quickly and conveniently by this program, and copies of the source program will be made available on request. Alkaline phosphatase activity must have been monitored until it has either reached a plateau (no stable component present) or is increasing linearly. The activity of any stable fraction present is calculated directly from the slope of the linear portion of the curve. This linear component is then 'peeled off' the original tracing by subtraction of the value of (slope X time) at various points along the tracing to give a curve which has levelled off. The chart paper is now turned upside down, and a horizontal line is drawn beneath the curve to meet it asymptotically. This line is equivalent to the abscissa (y-y') to curve D in Figure 3 . The ordinates of curve D are plotted on two-cycle sernilogarithmic graph paper (as in Fig. 2 ), and the linear portion is extrapolated to give an intercept on the ordinate. The slope has the value of -k 2 and the intercept the value C 2 !( -k 2), from which C 2 is calculated. As 
which is the equation for curve B' and is the typical output of the reaction rate analyser where the serum contained no urea stable isoenzyme. With relatively long t equation (4) simplifies to:
which gives the height of curve B' when inhibition is complete. Rearranging equation (4) we get:
Graphically, this step is equivalent to reflecting curve B' in the dotted axis ( Fig. 3 ) to give the curve D. This curve can be considered to represent the total components repetition of the subtraction/replotting procedure is necessary. EQUIPMENT The Vitatron automatic kinetic enzyme system (AKES) was used in enzyme mode for following the denaturation curve for the AP isoenzymes. The system is described in detail in the literature.P Empty vials are loaded into alternate positions in the specimen train. The diluter is primed with AP buffer-substrate, the reagent syringe is set at 700 ul, and the serum sample syringe is disabled at 0 !J.I. The empty vials activate the diluter dispensing 700 !J.l buffer-substrate into cuvettes thermostated at 37°. A Hamilton syringe (10 !J.l, model 801) was filled with up to 10 !J.l of specimen. The amount, which depends on the total AP activity, is chosen so that the degradation curve reaches completion within the range of the first absorbance scale of the instrument (0,05 optical density units for 100% deflection). When the first cuvette containing buffer-substrate is at the point prior to the measuring position, the specimen is added directly into the cuvette a few seconds before the stirrer withdraws and the cuvette moves into the optical light path (405 nm filter).
As the trace appears on the recorder the time since addition is marked on the chart. The cuvette is kept in the measuring position with the 'HOLD' switch until the reaction course has reached a plateau or becomes linear. A repeat injection is necessary if the trace goes on the second absorbance scale. With experience a reasonable estimate of the serum volume required can be made from the total AP value. It is usually possible to judge from the shape of the curve over the first minute whether plateau or linear conditions will be achieved within the first absorbance scale, and, if necessary, a re-injection can be made immediately.
REAGENTS
Reagents marketed by Clin-Tech for total AP determination on the Technicon SMA are used. p-Nitrophenol phosphate (0,5 g) is made up to 250 ml with 2-amino-2-methyl-l-propanol buffer (0' 625M, pH 10'25) and magnesium chloride solution (1' OM, O'5 m!) is added. Total AP was measured as part of a profile on the Technicon SMA using this reagent. For urea denaturation of AP, urea (4'2 g) was made up to 25 ml with the above buffersubstrate (2' 8 Murea).
TISSUE ENZYME PREPARATIONS
Postmortem liver, intestine, and infant cranial bone were obtained less than 24 hours after death, and the AP enzymes were extracted as described by Gerhardt 
Results
AP in the liver extract gave an activity degradation curve similar to curve B' 2 in Figure 3 . A semilogarithmic plot (OD v time) was a straight line indicative of a single isoenzyme component. The rate of degradation was dependent on temperature and urea concentration in the buffer-substrate mixture ( Table 1 ). AP extracted from infant cranial bone produced an activity degradation curve similar to that of B'l in Figure 3 , which also yielded a linear semilogarithrnic plot.
Degradation half-lives for bone AP were consistently less than those for the liver isoenzyme under corresponding conditions ( Table 1 ). The ability of the method to measure individual AP isoenzymes in the presence of other isoenzymes was demonstrated with mixtures in varying proportions of a Paget's disease serum and an extrahepatic cholestasis serum. Curves similar to B' in Figure 3were obtained which satisfactorily analysed into two isoenzyme components. At temperatures lower than 30°and/or buffer-substrate urea concentrations less than 2·5 molar, the half-lives became much longer, and the period to reach a plateau (approximately 7 half-lives of the more stable component) became inconveniently long. Urea concentrations higher than 3·0 molar at 37°caused the bone isoenzyme to degrade so fast that an inadequate length of degradation curve was produced for mathematical analysis. Convenient conditions for routine analysis were found at 37°with a urea buffer- substrate concentration of 2·8 molar, and these conditions were subsequently used throughout the study. Recovery experiments conducted with additions of known activities of liver and bone extracts respectively to heat denatured human serum (prepared at 60°for 30 minutes) were linear down to low values of activity and passed through the origin. Successive dilutions of several specimens containing approximately 100 IU/I liver isoenzyme and 200 IU/1 bone isoenzyme were analysed, and plotting 'recovered activity' versus 'activity present' gave results which passed through the origin for liver isoenzyme but which gave an intercept of -25 IU/1 for the bone isoenzyme (see Discussion). Normal serum with added extract of intestinal mucosa or pregnancy serum gave curves similar to A' in Fig. 3 as under the chosen conditions both intestinal and placental AP were stable, giving a linear increase in optical density after the initial curve due to the decay of bone and liver activity. The expected recoveries of each of the individual components were observed in these addition experiments.
Measurement of the precision of the injection technique, assessed by finding the total AP activity in the absence of urea, gave a CV = 2'5% at 400 IU11. Analyses for liver isoenzyme in a normal serum spiked with eight different quantities of bone extract (10--100 IU/l) gave a CV = 8'1% at 35 IV/I. A specimen containing high bone isoenzyme activity (435 IV/I) on serial dilution with heat denatured serum (1:1 to 1:16) gave results for bone AP activity with a CV = 17 %. Injection of successively smaller quantities of this specimen without dilution gave similar analytical performance. Duplicate analysis of 13 samples with values for liver AP ranging from normal up to 200 IV/I (mean value 79 IV/I) were
Brown and Lewis made. Using the formula v((,,£d2)/2n), where d is the difference between duplicates and n the number of pairs, the precision had a standard deviation of 9 IV11. Duplicate analyses for 10 specimens with bone activity values ranging from normal up to 200 IV/I (mean 108 IV/I) produced results with a SD of 20 IU/1.
A series of 63 serum samples, having normal bone/liver biochemical profiles from patients with no diagnosed condition relating to liver or bone pathology, were selected for establishing a reference range. Values for the total AP by the Technicon method were normally distributed giving a range (mean ± 2SD) of 40-120 IV/I, very close to the laboratory reference range. Values found for liver AP were normally distributed with a range (mean ± 2SD) of lQ-60 IV/I ( Table 2 ). The reference interval for bone isoenzymes was found to be Q-4O lUll, but values were not normally distributed: 60% of the specimens had values below the limit of detection (see Discussion). The reference range for total AP isoenzymes obtained by numerical addition of individual components was 10--80 IV/I, which is different from the SMA total AP range due to the modification of the buffer environment of the enzymatic reaction that is produced by the 2· 8M urea.
It was found that about 15 % of normal specimens had an extra urea degradable AP isoenzyme present with a half-life much longer than the usual liver isoenzyme. This isoenzyme was also seen in patients with liver disease but not in patients with bone disease. A wide variation of half-lives was found for both bone and liver enzymes (Table 2) although it was always possible to distinguish between them. Both half-life distributions were positively skewed with a range for liver isoenzymes of 0·53 to 4'7 minutes (mean = 1· 66, mode = 1· 4) and for the bone AP O·24 to 0·49 (mean = O' 35, mode = O' 31). 
The pregnancy case also had placental alkaline phosphatase present in the serum (26 lUll). The carcinoma rectum case has two liver components.
The sum of bone +liverisoenzyme does not equal total alkaline phosphatase because assays are carried out under different conditions.
The method was further evaluated by investigation of a series of 50 pathological specimens. A selection of results is shown in Table 2 . In all cases the results were consistent with isoenzyme identificationby electrophoresis and with the diagnosis.
Discussion
A major drawback to methods which monitor decay of enzyme activity has been the large number of individual activity determinations necessary to define accurately the multiphasic degradation curve. The present method overcomes this problem by observation of the complete course of inhibition in a single cuvette, the necessary number of data points (usually about 30) being read from the chart recorder trace. Although the present method has been developed on the Vitatron AK,ES analyser, it is also applicable to other kinetic enzyme analysers. The majority of hospital clinical chemistry departments already possess such equipment, and so the method is introducible without capital expenditure. Graphical calculation of the results is entirely feasible for the occasional special investigation, thereby allowing its application in laboratories without computing facilities, although its routine use would be greatly facilitated by the use of a computer to process the data in a similar manner to the FORTRAN program developed by the authors.
The method yields a wide variation in half-lives for the liver and bone isoenzymes, an effect that has also been noted in heat degradation methods. 8 The present method avoids difficulties from reliance on averaged half-life values because individual half-lives are calculated for each specimen, and these values can further be used as an additional method of quality control.
In 16 %ofcases a triphasic curve was obtained, the extra component usually having a relatively long half-life. This extra component was not seen in any cases of bone disease, and on the basis that the half-life values lay within the liver isoenzyme range, it is tentatively classified as due to liver isoenzyme, possibly arising by modification of the liver isoenzyme by proteolytic enzymes or by binding to other proteins in the serum. Another possibility is that this component corresponds to that designated as intestinal isoenzyme by other workers. 8 Reproducibility and sensitivity for the liver isoenzyme is good in the range found in normal specimens as well as in sera with increased liver isoenzyme activity. Performance for bone isoenzyme is less precise and less sensitive due to its shorter half-life. The extrapolation line for bone isoenzyme is much steeper than for liver isoenzyme, and consequently the calculated activity (and its precision) depends more critically on the value of the slope found by the least squares regression procedure.
Sensitivity for bone isoenzyme is related in part to the relative proportions of liver and bone activity present and also to their relative half-lives. As the maximum quantity of serum that can be injected into the cuvette is limited by the requirement that a plateau is attained for the degradable isoenzymes present, in the case of a serum with a very high proportion of liver isoenzyme there will be too little bone isoenzyme to be detected. Provided there is sufficient bone isoenzyme present to be 'seen', however, the correct value will be calculated for the activity, but below a critical bone:liver ratio (depending on relative half-lives) the bone isoenzyme will disappear. This is the reason for the 60 % of normal specimens having an apparent bone isoenzyme activity of zero. The liver isoenzyme is not similarly affected in the presence of large amounts of bone activity due to its longer half-life. Some improvement to allow study of bone isoenzyme activity in cases with normal livers might be obtained by working at 35°with 2·5 molar urea (Table 1 ) but this has not yet been explored fully.
Despite this drawback the method proves to be quite effective in the clinically important area where it is necessary to distinguish between a hepatobiliary or osteoblastic source of a marginally or moderately increased total AP activity. In no case was intestinal AP detected either on electrophoresis or by the urea degradation method, but in one case (Table 2) placental isoenzyme was measured in the serum of a patient with benign cholestasis of pregnancy.
Currently recognised uses of AP isoenzyme activity measurement include the detection of raised levels in occult liver or bone disease, particularly where the situation may be complicated by concomitant physiological bone growth or concurrent treatment with hepatic enzyme inducing drugs. Recently published work has shown a correlation of bone isoenzyme activity with both the serum growth hormone and the extent of bone remodelling in acromegaly.P Applications of the present method are by no means limited to the alkaline phosphatases or to use with urea. Other isoenzymes that have been studied using urea include lactate dehydrogenase'" and pseudocholinesterase," but other inhibitory agents (eg, p-nitrophenyl diethyl phosphate) have been used successfully with the pseudocholinesterases'" and degradation reagent guanidine thiocyanate has been applied to globular proteins in general." All these reagents belong to the class of irreversible inhibitors" and have the potential of application in the present method in a general
